ER PvuII and XbaI polymorphisms in postmenopausal women with posterior tibial tendon dysfunction: a case control study

Carregando...
Imagem de Miniatura
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
BMC
Autores
NOGARA, P. R. B.
FONSECA, F. C. P.
NETTO, C. Cesar
MAFFULLI, N.
SANTOS, M. C. L.
Citação
JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, v.13, article ID 316, 5p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
BackgroundPosterior tibial tendon (PTT) insufficiency is considered as the main cause of adult acquired flat foot and is three times more frequent in females. High estrogen levels exert a positive effect on the overall collagen synthesis in tendons. We have previously demonstrated the association between some genetic single-nucleotide polymorphism (SNP) and tendinopathy. In the present study, we investigated the association of PvuII c454-397T>C (NCBI ID: rs2234693) and XbaI c454-351A>G (NCBI ID: rs9340799) SNPs in estrogen receptor alfa (ER-) gene with PPT dysfunction.MethodsA total of 92 female subjects with PTT dysfunction, with histopathological examination of the tendon and magnetic resonance image (MRI) evidence of tendinopathy, were compared to 92 asymptomatic females who presented an intact PPT at MRI for PvuII and XbaI SNPs in the ER- gene. Genomic DNA was extracted from saliva and genotypes were obtained by polymerase chain reaction restriction fragment length polymorphism.ResultsThe analysis of PvuII SNPs showed no significant differences in the frequency of alleles and genotypes between control and PTT dysfunction groups. The XbaI SNPs in the ER- gene showed significant differences in the frequency of genotypes between control and test groups (p=0.01; OR 95% 1.14 (0.55-2.33).ConclusionsThe XbaI SNP in the ER gene may contribute to tendinopathy, and the A/A genotype could be a risk factor for PTT tendinopathy in this population. The PvuII SNP studied was not associated with PTT tendinopathy.
Palavras-chave
Tendinopathy, Estrogen receptor, Genetic polymorphism, Risk factor
Referências
  1. Aidar Marisi, 2007, Braz. Dent. J., V18, P148, DOI 10.1590/S0103-64402007000200012
  2. Baroneza JE, 2014, GENE, V547, P334, DOI 10.1016/j.gene.2014.07.001
  3. Bonato LL, 2016, INT J ORAL MAX SURG, V45, P323, DOI 10.1016/j.ijom.2015.10.007
  4. Bridgeman JT, 2010, FOOT ANKLE INT, V31, P1081, DOI 10.3113/FAI.2010.1081
  5. Munhoz FBD, 2016, J GENE MED, V18, P325, DOI 10.1002/jgm.2934
  6. de Jong JP, 2014, CLIN ORTHOP SURG, V6, P196, DOI 10.4055/cios.2014.6.2.196
  7. Diniz-Fernandes T, 2018, HISTOL HISTOPATHOL, V33, P929, DOI 10.14670/HH-11-982
  8. Ewies AAA, 2008, MOL HUM REPROD, V14, P127, DOI 10.1093/molehr/gam090
  9. Godoy-Santos A, 2014, SCAND J MED SCI SPOR, V24, P220, DOI 10.1111/j.1600-0838.2012.01469.x
  10. Godoy-Santos A, 2013, J ORTHOP RES, V31, P1103, DOI 10.1002/jor.22321
  11. Han ZH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006473
  12. Hansen M, 2014, EXERC SPORT SCI REV, V42, P183, DOI 10.1249/JES.0000000000000026
  13. Hu W, 2015, INT J CLIN EXP MED, V8, P1956
  14. Hu X, 2017, J BIOMED RES, V31, P213, DOI 10.7555/JBR.31.20160087
  15. Leblanc DR, 2017, J STEROID BIOCHEM, V172, P106, DOI 10.1016/j.jsbmb.2017.06.008
  16. Lee CA, 2015, J APPL PHYSIOL, V118, P1250, DOI 10.1152/japplphysiol.00823.2014
  17. Liu SH, 1997, AM J SPORT MED, V25, P704, DOI 10.1177/036354659702500521
  18. Magnusson SP, 2007, INT J EXP PATHOL, V88, P237, DOI 10.1111/j.1365-2613.2007.00551.x
  19. Motta GD, 2014, J SHOULDER ELB SURG, V23, P227, DOI 10.1016/j.jse.2013.07.053
  20. Neto JO, 2016, PLOS ONE S12, V11
  21. Park YS, 2017, BRIT J NEUROSURG, V31, P63, DOI 10.1080/02688697.2016.1206186
  22. Pomeroy GC, 1999, J BONE JOINT SURG AM, V81A, P1173, DOI 10.2106/00004623-199908000-00014
  23. Safarinejad MR, 2012, MOL CARCINOGEN, V51, pE104, DOI 10.1002/mc.21870
  24. Salles JI, 2015, J SCI MED SPORT, V18, P150, DOI 10.1016/j.jsams.2014.02.011
  25. Satomi E, 2008, CLINICS, V63, P9, DOI 10.1590/S1807-59322008000100003
  26. Schneider S, 2000, ARLEQUIN V 2 000 SOF
  27. Shen PC, 2015, INT J MOL SCI, V16, P26452, DOI 10.3390/ijms161125968
  28. Song CH, 2014, J HAND SURG-EUR VOL, V39, P155, DOI 10.1177/1753193413484873
  29. Sowers MR, 2008, J CLIN ENDOCR METAB, V93, P3958, DOI 10.1210/jc.2008-0482
  30. Sundermann EE, 2010, MENOPAUSE, V17, P874, DOI 10.1097/gme.0b013e3181df4a19
  31. Tashjian RZ, 2016, J SHOULDER ELB SURG, V25, P865, DOI 10.1016/j.jse.2016.02.019
  32. Teerlink CC, 2015, J SHOULDER ELB SURG, V24, pE31, DOI 10.1016/j.jse.2014.06.052
  33. Torricelli P, 2013, AGE, V35, P2125, DOI 10.1007/s11357-012-9500-0
  34. Vaughn NH, 2017, ORTHOP J SPORTS MED, V5, DOI 10.1177/2325967117724416
  35. Wang CG, 2017, ONCOTARGET, V8, P27627, DOI 10.18632/oncotarget.15271
  36. Wojtys EM, 2002, AM J SPORT MED, V30, P182, DOI 10.1177/03635465020300020601
  37. Zazulak BT, 2006, SPORTS MED, V36, P847, DOI 10.2165/00007256-200636100-00004
  38. Zhao YN, 2017, ONCOTARGETS THER, V10, P3203, DOI 10.2147/OTT.S132419
  39. Zhu HP, 2018, BMC ENDOCR DISORD, V18, DOI 10.1186/s12902-018-0230-x